Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Autores de IIS La Fe

• Abelardo Garcia De Lorenzo Mateos

  Autor

• Pilar Giraldo Castellano

  Autor

• 

  Javier De La Rubia Comos

  Autor

• José López Aldeguer

  Autor

• 

  Pilar Sierra San Miguel

  Autor

Participantes ajenos a IIS La Fe

• Hernández MT
• de Arriba F
• López Corral L
• Rosiñol L
• Paiva B
• Palomera L
• Bargay J
• Oriol A
• Prosper F
• Olavarría E
• Quintana N
• García JL
• Bladé J
• Lahuerta JJ

Grupos

• Hematología y Hemoterapia

Abstract

For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention.